| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3374753 | Journal of Infection | 2012 | 8 Pages |
Abstract
Up to 38% and 15% of HIV-HCV coinfected and HCV-monoinfected patients develop infections during pegIFN+RBV therapy but without any correlation to neutropenia. Antibacterial prophylaxis/treatment should be considered early in HIV-HCV coinfected patients developing CD4+ cell counts <200/μL during antiviral therapy as these patients have an increased risk of OIs.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
B.A. Payer, T. Reiberger, F. Breitenecker, M.C. Aichelburg, C. Schuster, P.M. Heil, T.M. Scherzer, P. Ferenci, A. Rieger, M. Peck-Radosavljevic, Vienna HIV & Liver Study Group Vienna HIV & Liver Study Group,